Novartis Ag (NVSEF) Equity Ratio (2016 - 2025)

Novartis Ag has disclosed Equity Ratio across 10 years of filings, most recently posting 0.42 for Q4 2025.

• Equity Ratio for Q4 2025 came in at 0.42, down 3.66% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.42 (down 3.66% YoY), and the FY2025 annual result was 0.42, down 3.66% from the prior year.
• Equity Ratio came in at 0.42 for Q4 2025 at Novartis Ag, down from 0.43 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.51 in Q4 2021 to a low of 0.42 in Q4 2025.
• The 5-year median for Equity Ratio is 0.47 (2023), against an average of 0.47.
• Across the five-year window, Equity Ratio jumped 4733.89% in 2021 and retreated 7.74% in 2024, its largest moves.
• Novartis Ag's Equity Ratio stood at 0.51 in 2021, then decreased by 1.69% to 0.51 in 2022, then slipped by 7.55% to 0.47 in 2023, then declined by 7.74% to 0.43 in 2024, then decreased by 3.66% to 0.42 in 2025.
• The last three Equity Ratio figures came in at 0.42 (Q4 2025), 0.43 (Q4 2024), and 0.47 (Q4 2023), per Business Quant data.